Tumor Activity Equipment
-
by Genmab A/Sbased in DENMARK
-mediated enhanced hexamerization. In preclinical settings, DuoHexaBody-CD37 has been shown to induce potent in vivo and in vitro anti-tumor ...
-
Manufactured by Senti Biosciencesbased in USA
The product profile of SENTI-301 has the potential to promote expansion and persistence of NK cells, and activate and recruit the body’s own immune cells into the solid tumor microenvironment for enhanced anti-tumor activity. ...
-
by Genmab A/Sbased in DENMARK
®-CD38 demonstrated enhanced complement-dependent cytotoxicity and potent anti-tumor ...
-
Manufactured by CytomX Therapeutics, Inc.based in USA
CX-072 is a wholly owned PD-L1-targeting Probody therapeutic for the treatment of cancer. Initial clinical data presented at the ASCO and ESMO 2018 Annual Meetings showed that CX-072 demonstrated tolerability and anti-tumor activity, while reducing activation of the immune system outside the tumor. Initial clinical translation ...
-
Manufactured by ENB Therapeuticsbased in USA
ETBR on the luminal surface of tumor blood vessels, creates a barrier to transendothelial migration and homing of T-cells from the vessel to the tumor by downregulating ICAM-1 (an adhesion molecule). ETBRI blockers restore ICAM-1 expression which is required for T-cells to leave the circulation and infiltrate the tumor. ...
-
Manufactured by Mersana Therapeuticsbased in USA
of efficacy, delivery and tolerability. Stimulator of Interferon Genes (STING) is a well-studied innate immune pathway capable of inducing anti-tumor immune activity. Our preclinical data show that the anti-tumor activity of Immunosynthen STING-agonist ADCs involves the targeted activation of the STING pathway ...
-
Manufactured by Rubius Therapeutics, Inc.based in USA
to activate and expand NK cells. It is expected to produce a broad and potent anti-tumor T cell response, an innate immune response and have anti-tumor activity in those tumor types with known sensitivity to T cell killing, including tumor types with high mutational burden, PD-L1 expression and ...
-
Manufactured by Adaptimmune LLCbased in USA
the engineered TCR that targets MAGE-A4. Preclinical data indicate that co-expression of CD8α may broaden the immune response against solid tumors and increase anti-tumor activity by leveraging CD4+ cells into CD8+ killer or cytotoxic T‑cells while retaining their CD4+ helper ...
-
Manufactured by Elpisciencebased in CHINA
ES002’s dual ATP-adenosine mechanism is a potentially powerful TME regulator and transformative cancer immunotherapy. In preclinical studies ES002 demonstrated significant single agent anti-tumor activity as well as an excellent tolerability profile. ES002 has also shown superior enzymatic inhibition and binding ...
-
based in USA
VOR33 is our lead eHSC product candidate designed to replace the standard of care in transplant settings. Once the VOR33 cells have engrafted, we believe that patients can be treated with anti-CD33 therapies, such as Mylotarg or VCAR33, with limited on-target toxicity, leading to durable anti-tumor activity and potential cures. In ...
-
Manufactured by SystImmune Inc.based in USA
upon treatment with PD-1 and CTLA-4 blocking antibodies, restoring their anti-tumor activity. SI-B003 is currently being evaluated as a single agent in clinical trials enrolling patients with a variety of solid tumor ...
-
Manufactured by MorphoSys AGbased in GERMANY
Pelabresib (CPI-0610) is an investigational selective small-molecule designed to promote anti-tumor activity by inhibiting the function of bromodomain and extra-terminal domain (BET) proteins to decrease the expression of abnormally expressed genes in cancer. The compound has demonstrated a wide therapeutic window, with activity seen at a 48 ...
-
Manufactured by MV BioTherapeutics SAbased in SWITZERLAND
Cancer immunotherapy has therapeutic efficacy in a limited number of patients. Cancer immunotherapy with immune checkpoint inhibitors (ICIs) increases anti-tumor immunity by blocking molecules that suppress anti-tumor activity. However, only a limited fraction of patients benefits from the therapeutic response obtained with these biologic ...
-
Manufactured by OSE Immunotherapeuticsbased in FRANCE
closely linked to tumor activity and responsiveness to T-cell-targeted ...
-
Manufactured by BK Medical Holding Company, Inc.based in USA
Fusing powerful real-time ultrasound images with pre-exam MRI data gives you better guidance to help accurately target lesions detected on the MRI images, potentially reducing the risk of missing high-grade tumors or under-staging tumors for active ...
-
Manufactured by Santa Cruz Biotechnology, Inc.based in USA
Pheophorbide a is a chlorophyll-related compound studied for its anti-tumor and anti-cancer ...
-
Manufactured by Elpisciencebased in CHINA
that blocking both pathways provides robust anti-tumor activity across several solid tumors, including colorectal, gastric, cholangiocarcinoma, pancreatic, and non-small cell lung cancer. Partial responses to ES104 as a monotherapy have been observed in heavily pre-treated cancer patients, who were resistant to currently approved anti-VEGF ...
-
Manufactured by CytomX Therapeutics, Inc.based in USA
Probody therapeutics are designed to outsmart cancer by exploiting the unique conditions of the tumor microenvironment to more effectively localize treatment to the tumor, while limiting activity in healthy tissues. These novel therapies are designed to take advantage of high levels of protease activity in the ...
-
based in SOUTH KOREA
OGB23501 is a first-in-class tri-specific tumor microenvironment (TME) immune activator, which simultaneously targets PD-1, CTLA-4, and VEGF. We aim to develop it as a potential backbone therapy for melanoma, NSCLC, HCC, and renal ...
-
Manufactured by Shanghai Henlius Biotech, Incbased in CHINA
(serplulimab injection, anti-PD-1 mAb), company’s first self-developed innovative monoclonal antibody, was approved by the NMPA for the treatment of Microsatellite Instability-High (MSI-H) solid tumors in March 2022, providing an alternative treatment option for patients with MSI-H solid tumors. Henlius actively promotes ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you